Developing ABI-171, a novel multi-kinase inhibitor for idiopathic pulmonary fibrosis. FDA Orphan Drug Designation. IND-ready.
Joined March 2017
- Tweets 17
- Following 22
- Followers 32
- Likes 3
Photos and videos
It's #NewMemberMonday!
🧬 @Aclid develops a unified compiance platform for biosecurity and biosafety, supporting lab operations, EH&S and quality management.
🧪 @AvantiBio develops novel therapies for fibrotic diseases and other complex conditions.
🦠 DuneX Biosciences provides yeast display–based antibody discovery and affinity maturation services to biotech and pharmaceutical companies.
🫀 Organos revolutionizes cardiac drug development through heart-on-a-chip technology.
⚗️ Thaeta produces peptides for research and synthesis, enhancing the peptide research experience.
🦠 ViroMissile, Inc. engineers virus-based delivery systems to precisely target and eliminate cancer cells.
1
3
99
Mar 17
Thrilled to announce that @AvantiBiosciences has been named a @ConnectSanDiego 2026 Cool Company! 🎉
We're developing ABI-171, an oral small molecule for idiopathic pulmonary fibrosis — a disease with no cure and urgent need for better treatments.
Honored to join this class of venture-ready San Diego startups. Big things ahead. 🫁
#IPF #Biotech #SanDiego #CoolCompanies2026
22
Feb 17
Big news 🚀 Avanti Biosciences has been named a @hellotmrc Deep Tech Pioneer, selected from 4,800 applicants across 108 countries in the 11th Hello Tomorrow Challenge!
We're developing ABI-171, a novel treatment for idiopathic pulmonary fibrosis (IPF), a devastating disease with urgent unmet need.
See you in Amsterdam, June 11-12, 2026! 🌍 👉 hello-tomorrow.org/global-su…
#DeepTechPioneers #HelloTomorrow2026 #IPF #Biotech
1
25
Feb 10
We are excited to announce that we will be presenting at Biocom's sold-out Global Partnering & Investor Conference. Join us to learn more about our latest innovations. #BiocomGPIC
app.sosha.ai/s/IoevxCyM
2
9
Feb 10
Excited to share that Avanti Biosciences has been selected to present at @Biocom's Global Partnering & Investor Conference, February 24-26 at The Lodge at Torrey Pines.
We'll share our progress on ABI-171, our therapy that demonstrates disease reversal in IPF.
9
Jan 30
Major milestone! 🎉 Avanti accepted into @nih_nhlbi Catalyze Program for ABI-171 development. NIH support includes: - Pivotal efficacy studies - GMP manufacturing - IND regulatory support IND filing Q3 2026! #NIHfunding #IPF #ClinicalTrials #Biotech
12
Jan 30
Excited to share our latest research in @IJMS_MDPI! 🔬 ABI-171 shows superior efficacy vs. current IPF treatments: ✅ Improved survival (p=0.04) ✅ Reduced fibrosis ✅ Dual-kinase inhibition Read more: doi.org/10.3390/ijms25211182… #IPF #Biotech
12
18 Mar 2022
Check out our first publication on our class of molecules and their activity on Multiple Sclerosis authors.elsevier.com/a/1em5h…
1
6 Sep 2017
"Avanti Biosciences Receives $1.9M SBIR Fast-Track Award to Further Treatment for Alzheimer’s Disease" linkedin.com/pulse/avanti-bi… on @LinkedIn
1
5 Sep 2017
Avanti Biosciences, Inc. receives Fast Track SBIR grant to support pre-IND work to treat Alzheimer's disease. avantibiosciences.com/fast-t…
Avanti Biosciences retweeted
20 Jul 2017
Alzheimer's diagnosis often mistaken, but new blood test may improve accuracy: sandiegouniontribune.com/bus…
3
3
Avanti Biosciences retweeted
1 May 2017
BREAKING NEWS: $400 million increase for Alzheimer’s research funding approved: bit.ly/2pOiY1R. #ENDALZ
6
260
378
22 Apr 2017
Green tea compound could help treat Down syndrome medicalnewstoday.com/article… /via @mnt
7 Apr 2017
It's tea time! How a daily cuppa can shield you from dementia dailym.ai/2oKjm0x via @MailOnline